Consultation on regulatory amendments regarding tramadol

From Health Canada

Current status: Closed

This consultation ran from June 16, 2018 to August 14, 2018

Canadians were invited to provide comments on a proposal to add tramadol to Schedule I of the Controlled Drugs and Substances Act (CDSA) and the Schedule to the Narcotic Control Regulations (NCR).

Join in: how to participate

Read our Notice to Interested Parties which provides more details on the proposal.

Send us an email

Send an email to hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca with your input or comments.

Participate by mail

Send a letter with your input or comments to the address in the contact information section.

Goals of the consultation

Tramadol is an opioid analgesic that is available by prescription to provide pain relief for many patients in Canada.

Like many prescription opioids, tramadol can produce euphoria and dependence. It can also cause effects that pose serious health risks, such as seizures and respiratory failure, especially when it is used improperly.

To help protect Canadians from the health risks of improper opioid use, we are proposing to add tramadol to the CDSA and NCR. This will help to prevent it from being diverted for unauthorized use, while maintaining its availability for legitimate medical and scientific use.

Related information

Contact us

Office of Legislative and Regulatory Affairs
Address Locator 0302A,
150 Tunney's Pasture Driveway, Main Stats Building
Ottawa ON  K1A 0K9

Email: hc.csd.regulatory.policy-politique.reglementaire.dsc.sc@canada.ca

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: